Page 61 - ARNM-3-3

Advances in Radiotherapy
& Nuclear Medicine LuPSMA response patterns on PSMA PET

doi: 10.4081/aiua.2024.12132 prostate cancer (WARMTH Act): A multicentre,
retrospective study. Lancet Oncol. 2024;25(2):175-183.
177
27. Emmett L, Subramaniam S, Crumbaker M, et al. [ Lu]
Lu-PSMA-617 plus enzalutamide in patients with metastatic doi: 10.1016/S1470-2045(23)00638-1
castration-resistant prostate cancer (ENZA-p): An open-
label, multicentre, randomised, phase 2 trial. Lancet Oncol. 31. Sartor O, Ledet E, Huang M, et al. Prediction of resistance
177
2024;25(5):563-571. to Lu-PSMA therapy by assessment of baseline circulating
tumor DNA biomarkers. J Nucl Med. 2023;64(11):1721-1725.
doi: 10.1016/s1470-2045(24)00135-9
doi: 10.2967/jnumed.123.266167
28. Feuerecker B, Tauber R, Knorr K, et al. Activity and adverse
177
events of actinium-225-PSMA-617 in advanced metastatic 32. John N, Pathmanandavel S, Crumbaker M, et al. Lu-PSMA
castration-resistant prostate cancer after failure of lutetium- SPECT quantitation at 6 weeks (Dose 2) predicts short
177-PSMA. Eur Urol. 2021;79(3):343-350. progression-free survival for patients undergoing
177 Lu-PSMA-I&T therapy. J Nucl Med. 2023;64(3):410-415.
doi: 10.1016/j.eururo.2020.11.013
29. Sathekge MM, Bruchertseifer F, Vorster M, Morgenstern doi: 10.2967/jnumed.122.264677
A, Lawal IO. Global experience with PSMA-based alpha 33. Neubauer MC, Nicolas GP, Bauman A, et al. Early response
therapy in prostate cancer. Eur J Nucl Med Mol Imaging. monitoring during [ Lu]Lu-PSMA I&T therapy with
177
2021;49(1):30-46. quantitated SPECT/CT predicts overall survival of mCRPC
doi: 10.1007/s00259-021-05434-9 patients: Subgroup analysis of a swiss-wide prospective registry
study. Eur J Nucl Med Mol Imaging. 2024;51(4):1185-1193.
30. Sathekge MM, Lawal IO, Bal C, et al. Actinium-225-PSMA
radioligand therapy of metastatic castration-resistant doi: 10.1007/s00259-023-06536-2

Volume 3 Issue 3 (2025) 53 doi: 10.36922/ARNM025110011